ArticleStem cells translational medicine2014
Effect of human Wharton's jelly mesenchymal stem cell paracrine signaling on keloid fibroblasts.
Article in Stem cells translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 60 citations in OpenAlex.
- Mesenchymal Stem Cells-Derived Exosomes: Next-Generation Nanomedicines Toward Scarless Wound Healing.International journal of nanomedicine · 2026Review
- Comprehensive analysis of keloid super-enhancer networks reveals FOXP1-mediated anti-senescence mechanisms in fibrosis.Cellular & molecular biology letters · 2025Article
- Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.Stem cell research & therapy · 2024Review
- Wharton's jelly stem cells delivered via a curcumin-loaded nanofibrous wound dressings improved diabetic wound healing via upregulating VEGF and IGF genes: An in vitro and in vivo study.Regenerative therapy · 2024Article
- An updated review of the immunological mechanisms of keloid scars.Frontiers in immunology · 2023Review
- Therapeutic role of exosomes and conditioned medium in keloid and hypertrophic scar and possible mechanisms.Frontiers in physiology · 2023Review
- TGF-β1 and CD68 immunoexpression in capsules formed by textured implants with and without mesh coverage: a study on female rats.Acta cirurgica brasileira · 2022Article
- Advances in the pathogenesis and clinical application prospects of tumor biomolecules in keloid.Burns & trauma · 2022Review
- Extracellular Vesicles from Thapsigargin-Treated Mesenchymal Stem Cells Ameliorated Experimental Colitis via Enhanced Immunomodulatory Properties.Biomedicines · 2021Article
- Skin regeneration is accelerated by a lower dose of multipotent mesenchymal stromal/stem cells-a paradigm change.Stem cell research & therapy · 2021Article
- Therapeutic Strategies by Regulating Interleukin Family to Suppress Inflammation in Hypertrophic Scar and Keloid.Frontiers in pharmacology · 2021Review
- An Update on the Potential of Mesenchymal Stem Cell Therapy for Cutaneous Diseases.Stem cells international · 2021Review
- Inhibition of growth of Asian keloid cells with human umbilical cord Wharton's jelly stem cell-conditioned medium.Stem cell research & therapy · 2020Article
- Handheld instrument for wound-conformal delivery of skin precursor sheets improves healing in full-thickness burns.Biofabrication · 2020Article
- Effect of Intracorporeal Human Adipose-Derived Stem Cells (hADSCs) on Corpora Cavernosa Transforming Growth Factor βResearch and reports in urology · 2020Article
- Review
- Enhanced Therapeutic Potential of the Secretome Released from Adipose-Derived Stem Cells by PGC-1α-Driven Upregulation of Mitochondrial Proliferation.International journal of molecular sciences · 2019Article
- Promotion of dermal regeneration using pullulan/gelatin porous skin substitute.Journal of tissue engineering and regenerative medicine · 2019Article
- A silk fibroin/decellularized extract of Wharton's jelly hydrogel intended for cartilage tissue engineering.Progress in biomaterials · 2019Article
- Role of mechanical and thermal damage in pericapsular inflammatory response to injectable silicone in a rabbit model.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Keloid scars are abnormal benign fibroproliferative tumors with high recurrence rates and no current efficacious treatment. Accumulating evidence suggests that human umbilical cord Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) have antifibrotic properties. Paracrine signaling is considered one of the main underlying mechanisms behind the therapeutic effects of mesenchymal stem cells. However, the paracrine signaling effects of WJ-MSCs on keloids have not yet been reported. The aim of this study is to investigate paracrine signaling effects of human WJ-MSCs on keloid fibroblasts in vitro. Human umbilical cords and keloid skin samples were obtained, and WJ-MSCs and keloid fibroblasts were isolated and cultured. One-way and two-way paracrine culture systems between both cell types were investigated. Plasminogen activator inhibitor-I and transforming growth factor-β2 (TGF-β2) transcripts were upregulated in keloid fibroblasts cultured with WJ-MSC-conditioned medium (WJ-MSC-CM) and cocultured with inserts, while showing lower TGF-β3 gene expression. Interleukin (IL)-6, IL-8, TGF-β1, and TGF-β2 protein expression was also enhanced. The WJ-MSC-CM-treated keloid fibroblasts showed higher proliferation rates than their control keloid fibroblasts with no significant change in apoptosis rate or migration ability. In our culture conditions, the indirect application of WJ-MSCs on keloid fibroblasts may enhance their profibrotic phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.